Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Ann Hepatol ; 18(4): 601-606, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31078440

RESUMO

INTRODUCTION AND OBJECTIVES: Four regimens are recommended for treating hepatitis C (HCV) genotype 1 infection. Study aims were to (1) compare frequencies of contraindicated drug interactions (XDDIs) when each HCV regimen is added to medication profiles of HCV-monoinfected patients, (2) quantify the proportion of patients with XDDIs to all four regimens and (3) determine covariates independently associated with having a XDDI to all four regimens. MATERIALS AND METHODS: A cross-sectional study was performed within Upstate New York Veterans Healthcare Administration. INCLUSION CRITERIA: (1) age ≥18 years, (2) HCV monoinfection and (3) available medication list. Data extracted were: demographics, comorbidities, and medication list. Primary outcome was XDDIs involving patient's home medications and each HCV regimen. University of Liverpool drug interaction website was used to define XDDIs. Two-way comparisons of regimens were performed using McNemar's test where p<0.0083 was considered statistically significant. Multivariate regression analyses were performed to determine predictors. RESULTS: Of the 4047 subjects, mean±standard deviation age was 59.8±7.6. Median (interquartile range) number of medications used was 7 [4-11]. Frequencies of XDDIs after the addition of each regimen ranged from 2.8% to 17.8% and were mostly statistically different from one another. There were 95 (2.3%) patients with XDDIs to all four regimens. Predictors of having XDDIs to all four regimens were ≥6 medications and HCV infection ≥10 years. CONCLUSION: The frequencies of XDDIs varied between HCV regimens. Number of medications and duration of HCV infection were predictors of having XDDIs to all four regimens.


Assuntos
Antivirais/efeitos adversos , Contraindicações de Medicamentos , Interações Medicamentosas , Hepatite C Crônica/tratamento farmacológico , Idoso , Ansiolíticos/efeitos adversos , Antiasmáticos/efeitos adversos , Anticoagulantes/efeitos adversos , Anticonvulsivantes/efeitos adversos , Antidepressivos/efeitos adversos , Antieméticos/efeitos adversos , Anti-Hipertensivos/efeitos adversos , Antipsicóticos/efeitos adversos , Benzimidazóis/efeitos adversos , Benzofuranos/efeitos adversos , Carbamatos/efeitos adversos , Estudos Transversais , Suplementos Nutricionais/efeitos adversos , Combinação de Medicamentos , Feminino , Fluorenos/efeitos adversos , Compostos Heterocíclicos de 4 ou mais Anéis/efeitos adversos , Humanos , Imidazóis/efeitos adversos , Masculino , Pessoa de Meia-Idade , Inibidores da Agregação Plaquetária/efeitos adversos , Polimedicação , Pirrolidinas/efeitos adversos , Quinoxalinas/efeitos adversos , Sofosbuvir/efeitos adversos , Sulfonamidas/efeitos adversos , Uridina Monofosfato/efeitos adversos , Uridina Monofosfato/análogos & derivados , Veteranos , Vitaminas/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA